Notice of National Cancer Institute (NCI) Participation in PAR-14-225 "Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01)"

Notice Number: NOT-CA-14-050

Key Dates
Release Date: July 2, 2014

Related Announcements
PAR-14-225

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating, effective immediately, in PAR-14-225, "Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01)."

The following sections of PAR-14-225 have been updated to reflect NCI's participation in this funding opportunity announcement.

Part 1. Overview Information

Components of Participating Organizations
National Institute on Drug Abuse (NIDA)
National Center for Complementary and Alternative Medicine (NCCAM)
National Cancer Institute (NCI)

Catalog of Federal Domestic Assistance (CFDA) Numbers
93.279; 93.213; 93.393

Part 2. Section VII. Agency Contacts

Scientific/Research Contact
Ann O'Mara, Ph.D., R.N., F.A.A.N.
National Cancer Institute (NCI)
Telephone: 240-276-7050
E-mail: omaraa@mail.nih.gov

Financial/Grants Management Contact

Sean Hine
National Cancer Institute (NCI)
Telephone: 240-276-6291
E-mail: hines@mail.nih.gov

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Ann O'Mara, Ph.D., R.N., F.A.A.N.
National Cancer Institute (NCI)
Telephone: 240-276-7050
Email: omaraa@mail.nih.gov

NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS)
USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.